Hester Biosciences approves financial statements at 39th AGM

Hester Biosciences Limited held its 39th Annual General Meeting (AGM) on 21 July 2026, approving all six resolutions with a requisite majority via electronic voting. The meeting adopted the audited standalone and consolidated financial statements for the financial year ended 31 March 2026. Shareholders also approved the declaration of a dividend on equity shares for the same period.

The meeting was conducted through Video Conferencing and Other Audio Visual Means, commencing at 10:32 a.m. and concluding at 11:08 a.m. Representations for a total of 4,796,189 shares, aggregating to 56.38% of the total paid-up equity share capital, were received. Mr. Tapan Shah, Practicing Company Secretary, was appointed as the scrutiniser to ensure the voting process was conducted in a fair and transparent manner.

Voting Results

All resolutions placed before the members were passed. The re-appointment of Mr. Sanjiv Gandhi, who retires by rotation, received 99.67% approval, while the re-appointment of Ms. Priya Gandhi as Executive Director was passed as a Special Resolution with 99.79% votes in favour.

Resolution Description	Type	Votes For	Votes Against	% For	% Against
Adopt standalone financial statements	Ordinary	4,739,708	1	100.00	Negligible
Adopt consolidated financial statements	Ordinary	4,739,708	1	100.00	Negligible
Declare dividend	Ordinary	4,739,708	1	100.00	Negligible
Re-appoint Mr. Sanjiv Gandhi	Ordinary	4,028,711	13,178	99.67	0.33
Ratify Cost Auditors remuneration	Ordinary	4,739,708	1	100.00	Negligible
Re-appoint Ms. Priya Gandhi	Special	4,729,813	9,896	99.79	0.21

Key Attendees

The meeting was attended by the Board of Directors, Key Managerial Personnel, and statutory auditors. Dr. Bhupendra Gandhi, Chairman of the Company, presided over the meeting. The Statutory Auditor's and Secretarial Auditor's reports contained no qualifications or adverse remarks.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.10%	-2.88%	+11.85%	+71.56%	+27.93%	-1.84%

Hester Biosciences Limited has completed the sale of its entire equity investment in Texas Lifesciences Private Limited for an aggregate consideration of INR 23 million. The transaction, which took place on July 8, 2026, involved the transfer of 543,248 equity shares representing an 11% stake to existing shareholders of the company. This move marks a complete exit from the investment, reducing Hester Biosciences' shareholding in Texas Lifesciences Private Limited from 11% to nil.

The divestment was executed in accordance with the terms previously approved by the Board of Directors of Hester Biosciences. The transfer of shares was concluded with existing shareholders of Texas Lifesciences Private Limited, and the company has consequently ceased to hold any equity shares in the entity following the closure of the deal.

Transaction Details

The disclosure was submitted to the exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Vinod Mali, Company Secretary & Compliance Officer of Hester Biosciences Limited. The key details of the transaction are outlined below: